|
Pembrolizumab (Keytruda)
|
Anti-PD-1 humanized monoclonal antibody indicated for melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, and MSI-H solid tumors.
|
|
|
Trastuzumab (Herceptin)
|
Recombinant humanized IgG1 monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) in metastatic and early-stage breast and gastric cancers.
|
|
|
Osimertinib (Tagrisso)
|
Third-generation, CNS-active EGFR-TKI that selectively inhibits EGFR-sensitizing and EGFR T790M resistance mutations in metastatic NSCLC.
|
|
|
Nivolumab (Opdivo)
|
Fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor used across multiple solid and hematological malignancies.
|
|
|
Imatinib (Gleevec)
|
Small-molecule selective BCR-ABL tyrosine kinase inhibitor revolutionizing outcomes for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
|
|
|
Cisplatin
|
Platinum-based antineoplastic alkylating agent inducing DNA cross-links and cellular apoptosis across testicular, ovarian, lung, and bladder carcinomas.
|
|
|
Paclitaxel (Taxol)
|
Antimicrotubule taxane stabilizing tubulin polymerization and preventing mitotic spindle breakdown in breast, ovarian, and lung cancers.
|
|
|
Rituximab (Rituxan)
|
Chimeric monoclonal antibody against the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, used in non-Hodgkin lymphomas and CLL.
|
|
|
Doxorubicin (Adriamycin)
|
Anthracycline topoisomerase II inhibitor and DNA intercalator widely utilized in breast cancer, lymphomas, and soft tissue sarcomas.
|
|
|
Tamoxifen
|
Selective estrogen receptor modulator (SERM) used for endocrine-receptor positive breast cancer treatment and recurrence chemoprevention.
|
|
